Drug reference
sarilumab
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Drug class
Musculoskeletal (DMARDs)
Mechanism of action
Human monoclonal antibody that binds to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), and has been shown to inhibit IL-6-mediated signaling through these receptors. IL-6 is produced by synovial and endothelial cells leading to local production of IL-6 in joints affected by inflammatory processes (eg, rheumatoid arthritis)
Common side effects
- Neutropenia
- Injection site erythema
- Urinary tract infection
- ANC <1000/mm³
- Injection site pruritics
- Injection site pain.
Related conditions
Frequently asked questions
What drug class is sarilumab?
sarilumab belongs to: Musculoskeletal.
How does sarilumab work?
Human monoclonal antibody that binds to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), and has been shown to inhibit IL-6-mediated signaling through these receptors. IL-6 is produced by synovial and endothelial cells leading to local production of IL-6 in joints affected by inflammatory processes (eg, rheumatoid arthritis)
What are the common side effects of sarilumab?
Neutropenia, Injection site erythema, Urinary tract infection, ANC <1000/mm³, Injection site pruritics, Injection site pain.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.